Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721806 | 1.00 | NPSR1 (0.36) | NPSR1PDE10AMEN1GAAKMT2A | |
| SCHEMBL720187 | 1.00 | NPSR1 (0.36) | NPSR1PDE10AMEN1GAAKMT2A | |
| SCHEMBL717763 | 0.87 | NPSR1 (0.34) | NPSR1PDE10A | |
| SCHEMBL717764 | 0.87 | NPSR1 (0.34) | NPSR1PDE10A | |
| SCHEMBL721626 | 0.85 | NPSR1 (0.37) | NPSR1PDE10AMEN1GAAKMT2A | |
| SCHEMBL720488 | 0.84 | NPSR1 (0.36) | NPSR1PDE10AMEN1GAAKMT2A | |
| SCHEMBL721037 | 0.84 | NPSR1 (0.32) | NPSR1PDE10A | |
| SCHEMBL721036 | 0.84 | NPSR1 (0.32) | NPSR1PDE10A | |
| SCHEMBL10252045 | 0.79 | PDE10A (0.50) | NPSR1PDE10AMEN1GAAKMT2A | |
| SCHEMBL1535575 | 0.79 | NPSR1 (0.41) | NPSR1PDE10AMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115724-A1 | METHOD OF CONTROLLING UNDESIRED VEGETATION | SYNGENTA CROP PROTECTION LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115724-A1 | METHOD OF CONTROLLING UNDESIRED VEGETATION | SYNGENTA CROP PROTECTION LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115724-A1 | METHOD OF CONTROLLING UNDESIRED VEGETATION | SYNGENTA CROP PROTECTION LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120053053-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053053-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053053-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010125332-A1 | METHOD OF CONTROLLING UNDESIRED VEGETATION | SYNGENTA LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010092339-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA LIMITED (GB) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053053-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES | DPYD, DHODH, TYMP | NPSR1 3040/4885PDE10A 1953/4885MEN1 4540/4885 |
| US-20120115724-A1 | METHOD OF CONTROLLING UNDESIRED VEGETATION | TYMS, DHFR, UNG | NPSR1 1800/4885PDE10A 2162/4885MEN1 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.